Renal Osteodystrophy With Hyperphosphatemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for renal osteodystrophy with hyperphosphatemia. 5 active patents protecting 2 drugs from 2+ originators. First major cliff: 2030. Daily refresh.

2
Approved drugs
5
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Renal Osteodystrophy With Hyperphosphatemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Fresenius Medcl Care 3 patents Sanofi 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating renal osteodystrophy with hyperphosphatemia. Each bar = one year. Y-axis scaled to peak year (3 patents).

2
27
3
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Phoslo
CALCIUM ACETATE
 Fresenius Medcl Care 3 76 — 2027-07-20
Renvela
SEVELAMER CARBONATE
 Sanofi 2 48 — 2030-12-06

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8592480 Phoslo method of use 80 2027-07-20
9089528 Phoslo method of use 75 2027-07-20
8591938 Phoslo method of use 73 2030-02-23
9095509 Renvela formulation 48 2030-12-06
9095509 Renvela formulation 48 2030-12-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9095509 Renvela formulation 48 2030-12-06
9095509 Renvela formulation 48 2030-12-06
8591938 Phoslo method of use 73 2030-02-23
9089528 Phoslo method of use 75 2027-07-20
8592480 Phoslo method of use 80 2027-07-20

Related